{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:45:09Z","timestamp":1790142309575,"version":"4.0.1"},"reference-count":97,"publisher":"Informa UK Limited","issue":"30","funder":[{"name":"National Institute for Health NIH","award":["R01-CA132946"],"award-info":[{"award-number":["R01-CA132946"]}]},{"name":"National Institute for Health NIH","award":["R21-CA155524"],"award-info":[{"award-number":["R21-CA155524"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,12,31]]},"DOI":"10.2217\/fon-2018-0325","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T16:51:58Z","timestamp":1532451118000},"page":"3199-3213","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["Gemtuzumab Ozogamicin for Treatment of Newly Diagnosed CD33-Positive Acute Myeloid Leukemia"],"prefix":"10.1080","volume":"14","author":[{"given":"Mohammed","family":"Gbadamosi","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL\u00a032610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder K","family":"Lamba","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL\u00a032610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604496"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13345"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-604520"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28129"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.55"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604512"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604538"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc010021y"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.483.014k40_483_490"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)01930-5"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5489.84"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-797712"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.2741\/4181"},{"issue":"20","key":"e_1_3_3_16_1","first-page":"198","article-title":"Calicheamicin \u03b3 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein N","year":"1988","unstructured":"Zein N , SinhaA, McGahrenW, EllestadG. Calicheamicin \u03b3 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science240(20), 198\u2013201 (1988).","journal-title":"Science"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3678"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.17.7464"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/chir.20990"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9600398"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207196"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053518"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2311"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403598"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1129903"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1365-1"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2017.7028"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.s.004"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.04.011"},{"issue":"6","key":"e_1_3_3_30_1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross PF","year":"2001","unstructured":"Bross PF , BeitzJ, ChenGet al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res.7(6), 1490\u20131496 (2001).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490482"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2964"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623447"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.141937"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3197"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.376.376"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3179"},{"issue":"79","key":"e_1_3_3_43_1","first-page":"37","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study","volume":"118","author":"Delaunay J","year":"2011","unstructured":"Delaunay J , RecherC, PigneuxAet al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood118(79), 37\u201338 (2011).","journal-title":"Blood"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.229"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3821"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26190"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084293"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.3628"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0604"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.199"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403350"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2784"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.187"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-398370"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1536"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.309"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.6846"},{"issue":"17","key":"e_1_3_3_63_1","first-page":"2155","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Guillaume O","year":"2016","unstructured":"Guillaume O , EstelleG, JullienGet al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood127(17), 2155\u20132157 (2016).","journal-title":"Blood"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2218-6"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt566"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.185"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3115"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1224-13.2013"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv092"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt666"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2513"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1421756"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802157"},{"issue":"1","key":"e_1_3_3_74_1","first-page":"3826","article-title":"CD33-single nucleotide polymorphism (CD33-SNP) score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: report from Children\u2019s Oncology Group AAML0531 trial","volume":"130","author":"Lamba J","year":"2017","unstructured":"Lamba J , ChauhanL, ShinMet al. CD33-single nucleotide polymorphism (CD33-SNP) score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: report from Children\u2019s Oncology Group AAML0531 trial. Blood130(Suppl. 1), 3826 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000638"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047399"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06326.x"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3825"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0396"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.988"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.147"},{"issue":"1","key":"e_1_3_3_82_1","first-page":"2526","article-title":"Drug transporter ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with gemtuzumab ozagamicin: a report from Children\u2019s Oncology Group AAML0531 trial","volume":"130","author":"Chauhan L","year":"2017","unstructured":"Chauhan L , AlonzoTA, WangJet al. Drug transporter ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with gemtuzumab ozagamicin: a report from Children\u2019s Oncology Group AAML0531 trial. Blood130(Suppl. 1), 2526 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21723"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0300-3"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056838"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-023556"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491506"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1077"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.768.768"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4050.4050"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.341"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527044"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.055822"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3936.3936"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506592"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.244"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2786"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:04Z","timestamp":1719125104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":97,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2018,12,31]]}},"alternative-id":["10.2217\/fon-2018-0325"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0325","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}